glioblastoma

[Nature Communications] Scientists developed a strategy to compare the epigenetic and transcriptional make-up of primary glioblastoma cells with patient-matched expanded potential stem cell (EPSC)-derived neural stem cells.

[Cell Death & Disease] Scientists found that RAN binding protein 10 (RANBP10) was overexpressed in glioblastoma (GBM), and high RANBP10 expression was closely linked to poor survival of patients with GBM.

[Cell Death Discovery] MeRIP-Seq revealed the m6A profile in the glioblastoma multiforme (GBM). Moreover, the m6A-related long non-coding RNA CASC9 expression was significantly elevated in the GBM tissue and its ectopic high expression was associated with poor survival, acting as an independent prognostic factor for GBM patients.

[Scientific Reports] Scientists compared the efficacy of focused modulation of a set of signaling pathways in two glioblastoma cell lines, U-251 MG and T98-G, using a panel of thirteen compounds targeting cell cycle progression, proliferation, epigenetic modifications, and DNA repair mechanism.

[Cell Death & Disease] Researchers studied the role of the Par3 protein (encoded by PARD3) in glioblastoma multiforme (GBM). GBM patient transcriptomic data and patient-derived culture analysis indicated diverse levels of expression of PARD3 across and independent from subtypes

[Cell Death Discovery] Investigators found that pyrvinium pamoate (PP) and Temozolomide (TMZ) had synergistic effect on inhibiting the viability of glioblastoma multiforme (GBM) cells, and PP induced inhibition of MGMT and enhanced the TMZ chemosensitivity of GBM cells through down-regulating Wnt/β-catenin pathway.